FcγRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients
- 31 May 2008
- journal article
- Published by Elsevier in Cancer Genetics and Cytogenetics
- Vol. 183 (1), 35-40
- https://doi.org/10.1016/j.cancergencyto.2008.02.001
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Rituximab, an Anti-CD20 Monoclonal Antibody: History and Mechanism of ActionAmerican Journal of Transplantation, 2006
- Non-Hodgkin Lymphoma: Diagnosis and TreatmentMayo Clinic Proceedings, 2005
- Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'AdulteJournal of Clinical Oncology, 2005
- Evolving Role of Rituximab in the Treatment of Patients with Non-Hodgkin's LymphomaFuture Oncology, 2005
- Cancer incidence and mortality in Europe, 2004Annals of Oncology, 2005
- From the bench to the bedside: ways to improve rituximab efficacyBlood, 2004
- Rituximab: Expanding Role in Therapy for Lymphomas and Autoimmune DiseasesAnnual Review of Medicine, 2004
- FcγR polymorphisms: Implications for function, disease susceptibility and immunotherapyTissue Antigens, 2003
- A ROLE FOR ANTIBODIES IN TUMOR IMMUNITYInternational Reviews of Immunology, 2003
- Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20Blood, 1994